Home Trending Stocks Stealth BioTherapeutics Corp (MITO) Stock Going Down in PreMarket, Here's What You...

Stealth BioTherapeutics Corp (MITO) Stock Going Down in PreMarket, Here’s What You Should Know

Stealth BioTherapeutics Corp (MITO) stock prices were up by a colossal 35% as of the market closing on May 6th, 2021, bringing the price per share up to USD$1.62. Subsequent pre-market fluctuations saw the price fall by 11.11%, bringing it down to USD$1.44.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Collaboration with DCN

The company reported having convened with the Division of Cardiology and Nephrology (DCN) to discuss the forecasted submission of a New Drug Application (NDA). Having discussed MITO’s Barth development program for the treatment of cardiomyopathy in Barth syndrome, the two entities met again in February 2021 and early April 2021 to further explore the program and its NDA submission.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Read More

NDA Rejection

As it stands the FDA deemed the existing clinical date available to be inadequate in the demonstration of substantial evidence of the effectiveness of MITO’s program, and, therefore, do not warrant an NDA review. The U.S. Food and Drug Administration did, however, suggest options for the company to pursue in the generation of additional data that could support MITO’s push for NDA approval.

ReCLAIM-2 Trial Milestone

February 2021 saw the announcement of the completion of enrollment of ReCLAIM-2 Phase 2b trial patients, culminating with 176 patients with geographic atrophy. MITO presented the design and preliminary baseline demographics for the ReCALIM-2 trial in February 2021.

Development Funding Agreement

The achievement of this milestone resulted in an addition USD$10 million tranche of development funding as per the Development Funding Agreement announced in November 2020. The Agreement to support the clinical trial of elamipretide was first closed in November 2020. In total, the company has collected USD$30 million to date and is qualified to be granted an additional USD$5 million following the NDA submission for the treatment of cardiomyopathy in Barth syndrome.

Solid Liquidity Position

Also in November of the fiscal year 2020, the company closed a registered direct offering that saw the company generate USD$3.2 million. The proceeds came from the sale of 2,844,446 American Depositary Shares (ADSs). Another registered direct offering was conducted in February 2021, with the company offering 2,339,000 ADSs to facilitate the generation of gross proceeds amounting to USD$4.7 million. As of December 31st, 2020, MITO reported USD$32.8 million in cash and cash equivalents.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for MITO

Having been given direction by the FDA, MITO is strategizing its next steps to facilitate the commercialization of its treatment for cardiomyopathy in Barth syndrome. Armed with a solid liquidity position, current and potential investors are hopeful that MITO can effectively leverage its resources to facilitate further growth and increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Related News

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam